Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist
Christopher J. Winrow, Anthony L. Gotter, Christopher D. Cox, et al.
Journal of Neurogenetics (2011) Vol. 25, Iss. 1-2, pp. 52-61
Closed Access | Times Cited: 255

Showing 1-25 of 255 citing articles:

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial
David Michelson, Ellen Snyder, Erin M. Paradis, et al.
The Lancet Neurology (2014) Vol. 13, Iss. 5, pp. 461-471
Closed Access | Times Cited: 480
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Tobias Atkin, Stefano Comai, Gabriella Gobbi
Pharmacological Reviews (2018) Vol. 70, Iss. 2, pp. 197-245
Open Access | Times Cited: 306
Orexin receptor antagonism for treatment of insomnia
W. Joseph Herring, Ellen Snyder, Kerry Budd, et al.
Neurology (2012) Vol. 79, Iss. 23, pp. 2265-2274
Closed Access | Times Cited: 298
Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials
W. Joseph Herring, Kathryn M. Connor, Neely Ivgy-May, et al.
Biological Psychiatry (2014) Vol. 79, Iss. 2, pp. 136-148
Closed Access | Times Cited: 257
The hypocretins/orexins: integrators of multiple physiological functions
Jingcheng Li, Zhian Hu, Luı́s de Lecea
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 332-350
Open Access | Times Cited: 229
The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
Chunmei Wang, Qinqin Wang, Bingyuan Ji, et al.
Frontiers in Molecular Neuroscience (2018) Vol. 11
Open Access | Times Cited: 163
Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial
W. Joseph Herring, Paulette Ceesay, Ellen Snyder, et al.
Alzheimer s & Dementia (2020) Vol. 16, Iss. 3, pp. 541-551
Open Access | Times Cited: 138
The Neurobiology of Sleep and Wakefulness
Michael D. Schwartz, Thomas S. Kilduff
Psychiatric Clinics of North America (2015) Vol. 38, Iss. 4, pp. 615-644
Open Access | Times Cited: 172
International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology
Anthony L. Gotter, Andrea L. Webber, Paul J. Coleman, et al.
Pharmacological Reviews (2012) Vol. 64, Iss. 3, pp. 389-420
Closed Access | Times Cited: 154
Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men
Hong Sun, William P. Kennedy, Darren Wilbraham, et al.
SLEEP (2013)
Open Access | Times Cited: 149
Discovery and development of orexin receptor antagonists as therapeutics for insomnia
Christopher J. Winrow, John J. Renger
British Journal of Pharmacology (2013) Vol. 171, Iss. 2, pp. 283-293
Open Access | Times Cited: 144
Physiology of the orexinergic/hypocretinergic system: a revisit in 2012
Jyrki P. Kukkonen
AJP Cell Physiology (2012) Vol. 304, Iss. 1, pp. C2-C32
Closed Access | Times Cited: 133
Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia
Christopher J. Winrow, Anthony L. Gotter, Christopher D. Cox, et al.
Neuropharmacology (2011) Vol. 62, Iss. 2, pp. 978-987
Closed Access | Times Cited: 121
Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone
Stephen R. Morairty, Florent G. Revel, Pari Malherbe, et al.
PLoS ONE (2012) Vol. 7, Iss. 7, pp. e39131-e39131
Open Access | Times Cited: 117
Discovery of [(2R,5R)‐5‐{[(5‐Fluoropyridin‐2‐yl)oxy]methyl}‐2‐methylpiperidin‐1‐yl][5‐methyl‐2‐(pyrimidin‐2‐yl)phenyl]methanone (MK‐6096): A Dual Orexin Receptor Antagonist with Potent Sleep‐Promoting Properties
Paul J. Coleman, John D. Schreier, Christopher D. Cox, et al.
ChemMedChem (2012) Vol. 7, Iss. 3, pp. 415-424
Closed Access | Times Cited: 115
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 114
Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists
Takashi Nagahara, Tsuyoshi Saitoh, Noriki Kutsumura, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 20, pp. 7931-7937
Closed Access | Times Cited: 109
Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia
Anthony J. Roecker, Christopher D. Cox, Paul J. Coleman
Journal of Medicinal Chemistry (2015) Vol. 59, Iss. 2, pp. 504-530
Closed Access | Times Cited: 107
Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?
Daniël Hoyer, Laura H. Jacobson
Neuropeptides (2013) Vol. 47, Iss. 6, pp. 477-488
Closed Access | Times Cited: 107
Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine
Lois E. Krahn, Donna L. Arand, Alon Y. Avidan, et al.
Journal of Clinical Sleep Medicine (2021) Vol. 17, Iss. 12, pp. 2489-2498
Open Access | Times Cited: 101
In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist
Carsten T. Beuckmann, Michiyuki Suzuki, Takashi Ueno, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 2, pp. 287-295
Open Access | Times Cited: 89
Pharmacotherapy of Insomnia
David N. Neubauer, Seithikurippu R. Pandi‐Perumal, D. Warren Spence, et al.
Journal of Central Nervous System Disease (2018) Vol. 10
Open Access | Times Cited: 86
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Is the glymphatic system the missing link between sleep impairments and neurological disorders? Examining the implications and uncertainties
Jennaya Christensen, Glenn R. Yamakawa, Sandy R. Shultz, et al.
Progress in Neurobiology (2020) Vol. 198, pp. 101917-101917
Closed Access | Times Cited: 72
Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease
Christopher D. Morrone, Radha Raghuraman, S. Abid Hussaini, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top